Amerikanische Gesellschaft für Hirudotherapie

Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome

Basic science / preclinical published in BMC complementary medicine and therapies (2026)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Klinische StudienSpeichel-PharmakologieSicherheit & InfektionskontrolleArzneimittelentwicklungGenomik & ProteomikBilden A et al. · BMC complementary medicine and therapies, 2026

Abstract

BACKGROUND: Metabolic syndrome (METS) is a multifactorial cardiometabolic disorder characterized by abdominal obesity, insulin resistance, hypertension, dyslipidemia, and hyperglycemia, substantially increasing the risk of type 2 diabetes and cardiovascular diseases. The variable effectiveness of lifestyle and pharmacological interventions has heightened interest in complementary approaches. Hirudotherapy, containing a wide range of bioactive compounds, may offer therapeutic benefits. This study aimed to evaluate the effects of hirudotherapy on metabolic parameters in a rat model of METS. METHODS: Twenty-four male Wistar rats were divided into four groups: Control (n = 6), METS (n = 6), METS + 4-week hirudotherapy (n = 6), and METS + 8-week hirudotherapy (n = 6). METS was induced through a modified high-fat and fructose-enriched diet. The effects of hirudotherapy on liver enzymes (AST, ALT), lipid profile (TG, LDL cholesterol, HDL cholesterol), hemodynamic parameters (systolic/diastolic blood pressure, mean arterial pressure, heart rate), glucose metabolism (OGTT, AUC), and liver histopathology were assessed. Pellet and water intake were monitored to evaluate possible influences on appetite regulation. RESULTS: Hirudotherapy demonstrated hepatoprotective activity, yielding significant reductions in AST and ALT levels (p < 0.05). TG levels increased in METS, while LDL cholesterol showed partial improvement and HDL cholesterol remained unchanged. Systolic blood pressure significantly decreased in the hirudotherapy-treated groups, with no significant differences in diastolic pressure or heart rate. OGTT and AUC analyses revealed improved glucose tolerance and reduced hyperglycemia following hirudotherapy (p < 0.05). Histopathology showed marked improvements in steatosis, sinusoidal dilatation, and hydropic degeneration, although minor hemorrhagic foci persisted. Differences in pellet consumption suggested a potential regulatory effect on appetite and metabolic balance. CONCLUSION: Hirudotherapy may exert beneficial effects in METS by improving liver function, modulating lipid metabolism, enhancing insulin sensitivity, and reducing inflammation. Its influence on food intake may further support metabolic homeostasis. These findings support hirudotherapy as a potential biotherapeutic approach and warrant further mechanistic and clinical investigations.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsMetabolic SyndromeMaleRatsRats, WistarInsulin ResistanceLiverLipidsDisease Models, Animal

Zusammenfassung

Metabolic syndrome (METS) is a multifactorial cardiometabolic disorder characterized by abdominal obesity, insulin resistance, hypertension, dyslipidemia, and hyperglycemia, substantially increasing the risk of type 2 diabetes and cardiovascular diseases.

Warum dies für die Hirudotherapie relevant ist

Contributes clinical evidence for the therapeutic application of leech therapy.

Zitation

Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome.

Bilden A et al. · BMC complementary medicine and therapies, 2026

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: March 18, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.